Cardiac-Related Death Linked with Uloric
Higher mortality rates than with allopurinol
The FDA has issued a drug safety communication to alert patients and clinicians of an increased risk of heart-related death among patients with gout receiving the urate-lowering agent febuxostat (Uloric) compared with those given allopurinol.